GET DAILY SIGNALSOramed Pharmaceuticals (ORMP) Q3 2026 Earnings Outlook: Portfolio Revaluations Take Center Stage
Key Takeaways
- Oramed Pharmaceuticals (NASDAQ: ORMP) is expected to report third-quarter 2026 results in mid-November, covering the three months ended September 30, 2026.
- The company has shifted from a drug developer into a healthcare and medical-technology operator and investment holder, meaning earnings now hinge heavily on investment revaluations rather than product revenue.
- Consensus estimates point to earnings of roughly $0.43 per share, though coverage is extremely limited and results have been highly volatile quarter to quarter.
- In the prior quarter, Oramed posted net income of $78.16 million, or $1.84 in diluted earnings per share (EPS), driven largely by fair-value gains on its portfolio holdings.
- Investors will be watching mark-to-market moves in key stakes such as Alpha Tau Medical, Scilex, and Lifeward, which have been the primary swing factors in recent results.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to ORMP.
- Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention in the market.
Earnings Context and Why It Matters
Oramed Pharmaceuticals has undergone a dramatic transformation. Once focused on developing an oral insulin capsule, the company completed a strategic transaction with Lifeward in March 2026 that transferred its oral-delivery technology platform and repositioned Oramed as an active owner and operator of medical-technology and healthcare assets. As a result, quarterly earnings are now shaped less by operating performance and more by the fair-value revaluation of its investment portfolio. This makes the Q3 2026 report a key checkpoint for investors trying to gauge whether the sizable gains that lifted recent quarters can persist, or whether market volatility across its holdings will weigh on results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
For the third quarter of 2026, the limited consensus estimate calls for earnings of about $0.43 per share, while revenue is expected to remain minimal as the company generates little top-line income following its strategic shift. These figures carry a wide margin of uncertainty: only a single estimate underpins the consensus, and Oramed's results are dominated by non-operating financial income tied to investment revaluations.
For context, Oramed reported net income of $78.16 million, or $1.84 in diluted EPS, in the second quarter of 2026, up from $13.29 million a year earlier. That surge was driven primarily by mark-to-market gains on holdings including Alpha Tau Medical, in which Oramed holds roughly a 17% stake. Given the outsized role of these fair-value adjustments, headline EPS can swing sharply between quarters and may diverge meaningfully from any single forecast. From what I see, this volatility is something worth monitoring closely in the upcoming print.
Market Reaction and Investor Sentiment
Heading into the Q3 2026 report, sentiment around ORMP reflects the company's unusual earnings profile. Because profits are driven by investment revaluations rather than recurring revenue, the stock has shown notable post-earnings volatility and a tendency to move independently of traditional operating metrics. Key risk factors include swings in the share prices of Alpha Tau, Scilex, and Lifeward, as well as the health of Oramed's real-estate-related loan positions. Investors also continue to monitor the company's cash position, which declined through 2026 as dividends and new investments were funded, adding a layer of caution around the upcoming print.
Forward Outlook and Key Factors to Monitor
The most important factor to watch after this report is the trajectory of Oramed's investment portfolio, since mark-to-market revaluations of Alpha Tau, Scilex, Lifeward, and real-estate holdings have become the primary driver of reported net income. Any regulatory or clinical progress at these portfolio companies could translate directly into fair-value adjustments on Oramed's balance sheet.
Liquidity is another critical area. Management has stated that current cash resources and commitments are expected to support planned activities for at least the next 12 months, but the company has also acknowledged that additional financing may be needed in the future. Investors should monitor whether the dividend remains sustainable given the decline in cash reserves.
Finally, watch for any update on strategic alternatives. Oramed has signaled that it is actively evaluating new investments and potential acquisitions, meaning the composition of its portfolio—and therefore the shape of future earnings—could change. The Q3 2026 release offers a timely window into whether these catalysts are translating into durable shareholder value. One thing that stands out here is how portfolio performance will likely dictate the next several quarters.
Exploring Tickeron AI Tools for Earnings Analysis
I often turn to Tickeron’s AI Screener when preparing for earnings season like this. It helps me quickly filter stocks based on technical patterns, fundamentals, and volatility metrics, which is especially useful for a name like ORMP where investment revaluations dominate the picture. The tool surfaces relevant comparisons and signals that complement my own review of the numbers. In my view, it adds a layer of efficiency when the data can shift so quickly from one quarter to the next.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ORMP's RSI Oscillator ascends from oversold territory
The RSI Indicator for ORMP moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 62 cases where ORMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ORMP just turned positive on November 10, 2026. Looking at past instances where ORMP's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ORMP entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.498). P/E Ratio (0.910) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in pharmaceutical preparations
Industry Biotechnology
Advertisement